Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Pharmaceutical Compounding topic
No spam. Unsubscribe anytime.
Industry group warns S.1497 could limit access to compounded 503B medications used by hospitals
Summary
An industry advocate told the Joint Committee the state should not restrict pharmacies’ ability to dispense compounded medications produced by FDA‑registered outsourcing facilities (503B), saying such a change could harm patients who rely on specialized formulations.
A representative of outsourcing‑facility stakeholders urged the Joint Committee on Public Health to oppose S.1497, which the witness said would restrict pharmacies’ ability to dispense compounded drug products from FDA‑registered outsourcing facilities (503B facilities).
Lee Rosebush said the Massachusetts Board of Pharmacy had previously adopted a policy consistent with federal practice allowing state‑licensed pharmacies to dispense 503B‑produced products, and that revoking that policy would remove access to certain life‑saving compounded products. He cited examples in which hospitals rely on 503B products—concentrated albuterol and desmopressin—so pediatric and hemophilia patients can be discharged with appropriate formulations that otherwise would require longer hospital stays.
Why it matters: The witness argued that 503B facilities operate under current‑good‑manufacturing‑practice (cGMP) oversight by the FDA and offer quality standards not always matched by traditional compounding pharmacies. Restricting their distribution chain could increase hospital stays and risk patient harm, he said.
Next steps: The witness asked the committee to reject S.1497 or to ensure any statutory change preserves the ability of hospitals and pharmacies to dispense 503B-compounded products for patient care.
